-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Apellis Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2015 to 2023.
- Apellis Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$29.4M, a 75.6% increase year-over-year.
- Apellis Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$313M, a 48.9% increase year-over-year.
- Apellis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$517M, a 13% increase from 2022.
- Apellis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$595M, a 10.9% decline from 2021.
- Apellis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$536M, a 151% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)